FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request
This article was originally published in The Rose Sheet
Based on its fiscal 2017 budget justification, FDA does not support a congressional proposal to formalize Cosmetic Ingredient Review safety assessments through a public-private partnership. The agency still intends to prepare a report on the subject, as directed by Senate and House appropriations committees, but characterizes the proposed framework as "inappropriate."
You may also be interested in...
CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.
FDA’s Holiday Gift To Cosmetics Industry: 10ppm Recommended Lead Cap
FDA affirms in draft guidance that a maximum lead level of 10 parts per million in cosmetic products does not pose a health risk to consumers, establishing a position consistent with the Personal Care Products Council’s recommendation in 2011. The formal stance from FDA could take some heat off of manufacturers, though the Environmental Working Group says it will continue pushing for tighter restrictions.
CIR Panel Plans For Lead Acetate Review At FDA’s Request
While FDA has gone on record as being leery of proposed legislation that would formalize its relationship with the Cosmetic Ingredient Review, the agency continues to leverage the industry-funded program’s expertise. At FDA’s request, the CIR Expert Panel will review progressive hair dye lead acetate in 2017.